In other words, even after the traditional selection based on RAS and BRAF and tumor sidedness, approximately one-third of patients do not respond to EGFR-inhibition, indicating that additional molecular escape mechanisms limit therapeutic efficacy [142]. Here, EGFR is linked to neoplasm.